Bessemer Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.28M Buy
70,632
+11,584
+20% +$675K 0.01% 533
2025
Q4
$3.19M Sell
59,048
-4,979
-8% -$240K ﹤0.01% 633
2025
Q3
$2.89M Buy
64,027
+4,507
+8% +$210K ﹤0.01% 434
2025
Q2
$2.75M Sell
59,520
-7,040
-11% -$346K ﹤0.01% 424
2025
Q1
$4.06M Sell
66,560
-38,240
-36% -$2.23M 0.01% 380
2024
Q4
$5.93M Sell
104,800
-3,375
-3% -$189K 0.01% 381
2024
Q3
$5.6M Sell
108,175
-812
-0.7% -$38.1K 0.01% 400
2024
Q2
$4.53M Sell
108,987
-50,079
-31% -$2.24M 0.01% 381
2024
Q1
$8.63M Buy
159,066
+22,286
+16% +$1.14M 0.02% 325
2023
Q4
$7.02M Buy
136,780
+42,674
+45% +$2.24M 0.01% 337
2023
Q3
$5.46M Sell
94,106
-2,290
-2% -$140K 0.01% 344
2023
Q2
$6.16M Buy
96,396
+14,149
+17% +$949K 0.01% 326
2023
Q1
$5.7M Sell
82,247
-7,781
-9% -$549K 0.01% 322
2022
Q4
$6.48M Sell
90,028
-4,765
-5% -$359K 0.02% 299
2022
Q3
$6.74M Buy
94,793
+6,733
+8% +$488K 0.02% 289
2022
Q2
$6.78M Buy
88,060
+1,961
+2% +$149K 0.02% 265
2022
Q1
$6.29M Buy
86,099
+12,926
+18% +$868K 0.01% 240
2021
Q4
$4.56M Sell
73,173
-2,856,716
-98% -$168M 0.01% 255
2021
Q3
$173M Buy
2,929,889
+25,014
+0.9% +$1.65M 0.37% 78
2021
Q2
$194M Buy
2,904,875
+106,733
+4% +$6.96M 0.42% 66
2021
Q1
$177M Buy
2,798,142
+158,822
+6% +$9.88M 0.42% 66
2020
Q4
$164M Buy
2,639,320
+343,869
+15% +$21.1M 0.43% 65
2020
Q3
$138M Buy
2,295,451
+2,187,013
+2,017% +$132M 0.41% 72
2020
Q2
$6.38M Buy
108,438
+48,101
+80% +$2.88M 0.02% 273
2020
Q1
$3.36M Buy
60,337
+13,930
+30% +$851K 0.01% 336
2019
Q4
$2.98M Buy
46,407
+6,415
+16% +$367K 0.01% 458
2019
Q3
$2.03M Sell
39,992
-11,764
-23% -$553K 0.01% 517
2019
Q2
$2.35M Sell
51,756
-2,717
-5% -$127K 0.01% 480
2019
Q1
$2.6M Buy
54,473
+650
+1% +$32.4K 0.01% 393
2018
Q4
$2.8M Buy
53,823
+5,369
+11% +$288K 0.01% 293
2018
Q3
$3.01M Sell
48,454
-1,817
-4% -$108K 0.01% 310
2018
Q2
$2.78M Sell
50,271
-1,733,480
-97% -$93.6M 0.01% 326
2018
Q1
$113M Buy
1,783,751
+12,675
+0.7% +$815K 0.44% 86
2017
Q4
$109M Sell
1,771,076
-12,158
-0.7% -$760K 0.42% 90
2017
Q3
$114M Buy
1,783,234
+1,159
+0.1% +$67.7K 0.45% 87
2017
Q2
$99.3M Sell
1,782,075
-2,156,963
-55% -$117M 0.4% 93
2017
Q1
$214M Buy
3,939,038
+667,795
+20% +$36.6M 0.89% 31
2016
Q4
$191M Buy
3,271,243
+1,037,485
+46% +$56.7M 0.88% 23
2016
Q3
$120M Buy
2,233,758
+136,697
+7% +$8.78M 0.61% 57
2016
Q2
$154M Sell
2,097,061
-834
-0% -$58.9K 0.85% 30
2016
Q1
$134M Buy
2,097,895
+242,367
+13% +$15.3M 0.76% 31
2015
Q4
$128M Buy
1,855,528
+21,209
+1% +$1.4M 0.71% 44
2015
Q3
$109M Buy
1,834,319
+455,754
+33% +$28.9M 0.62% 55
2015
Q2
$91.7M Buy
1,378,565
+455,291
+49% +$30M 0.48% 78
2015
Q1
$59.6M Buy
923,274
+824,583
+836% +$51.6M 0.3% 108
2014
Q4
$5.83M Buy
98,691
+3,537
+4% +$199K 0.03% 239
2014
Q3
$4.87M Sell
95,154
-5,438
-5% -$272K 0.03% 258
2014
Q2
$4.88M Sell
100,592
-2,506
-2% -$123K 0.03% 244
2014
Q1
$5.35M Sell
103,098
-16,753
-14% -$891K 0.04% 211
2013
Q4
$6.37M Buy
119,851
+22,249
+23% +$1.13M 0.05% 194
2013
Q3
$4.52M Sell
97,602
-4,940
-5% -$217K 0.04% 226
2013
Q2
$4.58M Buy
+102,542
New +$4.45M 0.04% 216

Other funds holding BMY

Bessemer Group's BMY Position: Q1 2026 in Review

Bessemer Group increased its Bristol-Myers Squibb (BMY) stake by 20% in Q1 2026, buying an estimated $675K and bringing the position to 70,632 shares worth $4.28M. The position accounts for 0.01% of the portfolio, ranked #533.

Bessemer Group first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $214M in Q1 2017. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Bessemer Group held 70,632 shares of Bristol-Myers Squibb worth $4.28M as of Q1 2026.
  • Bessemer Group bought 11,584 Bristol-Myers Squibb shares in Q1 2026, an estimated $675K.
  • Bristol-Myers Squibb made up 0.01% of Bessemer Group's portfolio in Q1 2026, its #533 holding.
  • Bessemer Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Bessemer Group's Bristol-Myers Squibb position peaked at $214M in Q1 2017.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.